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Purpose. To investigate the effectiveness and safety of combined phacoemulsification and dexamethasone intravitreal implant in
patients with cataract and diabetic macular edema. Methods. In this two-center, retrospective, single-group study, the charts of
16 consecutive patients who underwent combined phacoemulsification and intravitreal dexamethasone implant were
retrospectively reviewed. These 16 patients, 7 men and 9 women, were observed at least 3 months of follow-up. Primary
outcome was the change of the central retinal thickness (CRT); secondary outcome was the change of best-corrected visual
acuity (BCVA). Any ocular complications were recorded. Results. Mean CRT decreased significantly from 486± 152.4 μm at
baseline to 365.5± 91 μm at 30 days (p = 005), to 326± 80 μm at 60 days (p = 0004), and to 362± 134 μm at 90 days (p = 001).
Mean BCVA was 20/105 (logMAR, 0.72± 0.34) at baseline and improved significantly (p ≤ 007) at all postsurgery time points.
One case of ocular hypertension was observed and successfully managed with topical therapy. No endophthalmitis or other
ocular complications were observed. Conclusion. Intravitreal slow-release dexamethasone implant combined with cataract
surgery may be an effective approach on morphologic and functional outcomes for patients with cataract and diabetic macular
edema for at least three months after surgery.
1. Introduction
Diabetes mellitus is associated with a 5-fold higher prevalence
of cataract compared to the nondiabetic population [1]. Thus,
cataract extraction is a frequently performed surgical proce-
dure in patients with diabetes. Compared to nondiabetic cata-
ract patients, this surgery is associated with a higher risk of
complications in diabetic patients, including postsurgical
development of cystoid macular edema (also called Irvine-
Gass syndrome) or worsening of preexisting macular edema
[2–4]. Diabetic macular edema (DME) is a complication of
diabetic retinopathy and is the most common cause of visual
loss in both proliferative and nonproliferative diabetic reti-
nopathy. Approximately 20% of the patients with diabetic
retinopathy are affected by macular edema [5].
Currently, there is no standard treatment approach for
improving outcomes of cataract extraction in diabetic patients
with different degrees of clinically significant macular edema.
Previous papers proposed a combined approachwith intravit-
real injection of humanized anti-VEGF monoclonal antibod-
ies (ranibizumab, bevacizumab) or triamcinolone acetonide
and cataract surgery inpatientwithDME[6–12]. In aprospec-
tive, randomized clinical trial of intravitreous bevacizumab
versus triamcinolone when administered at the time of cata-
ract surgery, both groups gainedvision but only triamcinolone
acetonide was associated with a sustained reduction in central
macular thickness after six months [13].
Dexamethasone intravitreal implant (Ozurdex®; Allergan
Inc., Irvine, CA, USA) is a biodegradable implant that releases
a small amount (700 μg) of the glucocorticoid dexamethasone
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over a period of up to six months. Ozurdex is indicated for the
treatment of adult patients with visual impairment due to
diabetic macular edema who are pseudophakic or who are
considered insufficiently responsive to or unsuitable for non-
corticosteroid therapy or macular edema following either
branch retinal vein occlusion or central retinal vein occlusion,
or inflammation of the posterior segment of the eye presenting
as noninfectious uveitis.
In a prospective controlled, randomized interventional
pilot trial, the intravitreal dexamethasone implant at the
beginning of phacoemulsification significantly reduced cen-
tral macular thickness and increased visual acuity after a
24-week follow-up [14]. But only two papers analyzed the
safety and efficacy of Ozurdex implant at the end of cataract
surgery in patients with diabetic macular edema [15, 16].
So, in this study, we contribute to analyze the effective-
ness of intravitreal administration of dexamethasone implant
at the end of cataract surgery in diabetic patients with coex-
isting cataract and clinical significant macular edema in
order to avoid any increase of macular edema following
uncomplicated phacoemulsification and to obtain the better
functional outcome.
2. Methods
This was a two-center, non-randomized, retrospective,
single-group study of combined cataract surgery with intra-
vitreal dexamethasone implant (Ozurdex) in consecutive
diabetic patients with a diagnosis of cataract and clinically
significant diabetic macular edema as defined by the Early
Treatment Diabetic Retinopathy Study (ETDRS) [17].
The primary objective was to assess if intravitreal dexa-
methasone implant (Ozurdex) injection immediately after
cataract surgery was able to reduce or stabilize central retinal
thickness (CRT). The secondary objective was to assess
changes of best-corrected visual acuity (BCVA) throughout
the follow-up.
Safety evaluation has also been performed as regard intra-
ocular pressure (IOP) variations throughout the follow-up
period and incidence of other ocular adverse events (ocular
inflammation and other complications, such as retinal detach-
ment or endophthalmitis).
Patients who met all of the following criteria were consid-
ered for inclusion into the study: glycated haemoglobin≤ 9%,
controlled blood pressure (≤130/80mmHg), visually signifi-
cant cataract diagnosed using a slit lamp; nonproliferative
diabetic retinopathy and clinically significant macular edema;
tomographic features of nontractional diabetic macular
edema, cystoid pattern, and retinal detachment pattern as
described by Koleva-Georgieva [18], regardless of central
retinal thickness; and proliferative diabetic retinopathywhose
proliferative component had been previously treated with
laser photocoagulation. Patients whomet any of the following
criteria were excluded from study entry: treatment of diabetic
macular edema with intravitreal anti-VEGF in 3 months
before surgery or any type of intravitreal corticosteroid in the
6 months before surgery; presence of untreated proliferative
diabetic retinopathy; history of ocular hypertension or glau-
coma; and presence of associated conditions, such as uveitis,
retinal vein occlusion, and neovascular glaucoma, that could
worsenmacular edema. Patients who experienced intraopera-
tive complications, such as posterior capsular tear or vitreous
loss, were also excluded.
All patients underwent uneventful phacoemulsification
in bag hydrophilic acrylic intraocular lens (IOL) implant
using a 2.5mm clear cornea tunnel and dispersive ophthal-
mic viscoelastic device. Ozurdex (700 μg dexamethasone)
was administered via intravitreal injection under topical
anesthesia directly at the end of cataract surgery, in the infer-
otemporal quadrant. Patient data (age, gender, and medical
history with regard to diabetes and diabetic retinopathy)
were recorded from the patient’s medical file. CRT was mea-
sured using optical coherence tomography (TOPCON 3D
OCT-2000 or CIRRUS, Zeiss). BCVA was measured by using
a standardized ETDRS protocol [17]. Testing was done at a
standardized distance (4m) under standardized lighting con-
ditions. ETDRS values were converted into Snellen fraction
and then in logMAR values for the purpose of statistical
analysis. IOP was measured using a Goldmann tonometer.
Measurements of BCVA and CRT at different time points
of interest (baseline, 30, 60, and 90 days after surgery) were
retrospectively reviewed. IOP measurements at baseline, 10,
20, 30, 40, 50, 60, and 90 days after surgery were reviewed.
Ocular and systemic complications were recorded. A total
of 20 patients underwent combined phacoemulsification
and dexamethasone implant and met inclusion criteria. All
functional and morphologic data at baseline and at all post-
baseline time points up to 90 days after surgery were available
for only16 patients. Four patients missed the follow-up at 90
days. 16 consecutive patients were included in this study.
Statistical analysis was based on all patients included in the
study. Baseline was defined as the day before surgery. Data
processing, summaries, and analyses were performed using
the statistical software package SAS version 9.1 or higher.
A t-test was performed on the change from baseline in
CRT to evaluate a reduction or stabilization of CRT and
on the change from baseline in BCVA to evaluate an
improvement of visual acuity. No formal sample size calcu-
lation was performed.
3. Results
Population’s characteristics and relevant medical history data
with regard to the underlying disease are summarized in
Table 1. 16 consecutive patients out of 20 diabetic patients
who underwent combined phacoemulsification and dexa-
methasone slow-release implant were included in this study.
Mean age of the 7 men and 9 women included in this study
was 62.5± 13.4 years (range: 31–76). Most patients (n = 15)
had type 2 diabetesmellitus; only 1 patient had type 1 diabetes
mellitus. The mean duration of diabetes was 20.1± 7.6 years
and rangedbetween2and30years.Themeanvalueof glycated
haemoglobin (HbA1c) was 7.76± 0.7% (range: 6.3–9). All
patients were treated for diabetes with insulin. Fourteen
patients had nonproliferative diabetic retinopathy, and 2
patientswith type2diabetes hadproliferativediabetic retinop-
athy. The mean CRT decreased significantly from 486±
152.4 μm at baseline to 365.5± 91 μm at 30 days (p = 005),
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to 326± 80 μm at 60 days (p = 0004), and to 362± 134 μm at
90 days (p = 001) after surgery (Figure 1). The largest mean
(160± 142 μm) and median (116 μm) reduction were
observed at 60 days.A large standard deviation for the changes
from baseline in CRT was observed (Table 2).
The mean BCVA was 20/105 (logMAR, 0.72± 0.34)
at baseline. At the postsurgery time points, the mean
BCVA improved significantly to 20/60 (logMAR, 0.48±
0.28) at 30 days (p = 007), 20/53 (logMAR, 0.42± 0.30)
at 60 days (p = 0008), and 20/57 (logMAR, 0.46± 0.39)
at 90 days (p = 004) (Figure 2). The largest mean and
median improvement of 0.30 logMAR were seen at 60
days (Table 3).
Measurements of IOP over time are summarized in
Table 4. Mean and median IOP values were within normal
ranges at baseline and at all postsurgery time points.
Ocular hypertension (28mmHg) was observed in only
one patient 10 days after surgery. The condition was well
controlled with local therapy (dorzolamide/timolol fixed
combination 2 times/day). No other ocular or systemic
complications were observed.
4. Discussion
Phacoemulsification with in-the-bag IOL implantation, in
general, do not cause progression of diabetic retinopathy
[19–21]. However, previous studies suggested that diabetic
patients with macular edema who were undergoing cataract
surgery have poorer visual outcomes [20, 21]. So thanks to
intravitreal dexamethasone implant after cataract surgery,
patients with coexisting cataract and DME can benefit from
downregulation of inflammatory mediators and reduction
Table 1: Demographic characteristics and relevant medical history with regard to diabetes.
Total population (N = 16)
Age [years]
N 16
Mean (SD) 62.5 (13.4)




Duration of diabetes [years]
Mean (SD) 20.1 (7.6)
Median (min, max) 21.5 (2, 30)
Type of diabetes mellitus [n (%)]∗
Type 1 1 (6.3%)
Type 2 15 (93.7%)
Treatment of diabetes [n (%)]∗ Insulin 16 (100.0%)
Hba1c [%]
Mean (SD) 7.76 (0.7)
Median (min, max) 7.70 (6.3, 9)
Classification of diabetic retinopathy [n (%)]∗
Nonproliferative 14 (87.5%)
Proliferative 2 (12.5%)






























Figure 1: Boxplot of central retinal thickness (CRT) (μm) over 90 days. Mean CRT significantly decreased (p ≤ 005), mainly at 60 days after
combined approach.
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of breakdown of the blood-retinal barrier due to diabetic
status and surgical inflammatory stress.
With regard to the treatment of DME, dexametha-
sone slow-release implant (Ozurdex) has been shown to
achieve a similar rate of visual acuity improvement
compared with the anti-VEGF monoclonal antibody bev-
acizumab, with superior anatomic outcomes and fewer
injections [22].
In previous studies, we successfully experienced the use
of dexamethasone implant in refractory postsurgical macular
edema [23, 24]. The study reported here investigated the
effect of combining an intravitreal dexamethasone implant
(Ozurdex) with cataract surgery in patients with coexisting
cataract and clinically significant diabetic macular edema
on visual acuity, retinal thickness, and safety parameters.
Sixteen patients (7 men and 9 women) with cataract and
DME were included.
In a small prospective clinical trial on 18 eyes with
DME, dexamethasone implant was performed at the
beginning of phacoemulsification [14]. We considered per-
forming safer implant at the end of cataract surgery when
potential intraoperative complications were overcome and
a better visualization of implant in the vitreous was possible.
A prospective study published byPanozzo et al. [15] suggested
that intravitreal dexamethasone implant performed at the end
of phacoemulsification and IOL implantation was safe and
effective in naïve and refractory DME. Same results were
reported in a small case series which included 12 patients with
macular edema secondary to diabetic retinopathy and 12
patients with macular edema secondary to retinal vein
occlusion [16].
In our study, mean preoperative CRT (486± 152.4 μm)
was higher than that reported in previous papers (335.9±
90.6 μm [14], 451±NR μm [15], and 393± 166.5 μm [16])
with a wide range of value (270–789 μm) suggesting the
heterogeneity of DME feature as a target for steroid therapy.
In our study, the mean reduction in CRT was statistically
significant at 30, 60, and 90 days (p ≤ 005). Similar to previ-
ous reports [14–16], the greatest mean reductions in CRT
occurred at 30 (120.5 μm) and 60 days (160 μm) after
implant, with a recurrence of macular edema from the third
month. After the mean reduction in CRT reaches the highest
point, when dexamethasone reaches the highest concentra-
tion in the vitreous humor, the reduction in retinal thickness
decreases in line with the known pharmacodynamics of the
Ozurdex [25].
Table 2: Central retinal thickness (CRT) over time.
Measured CRT [μm]
Visit Baseline 30 days 60 days 90 days
Mean (SD) 486 (152.4) 365.5 (90.9) 325.8 (80.4) 361.7 (133.8)
Median (min, max) 503 (270, 789) 351 (251, 531) 305 (213, 499) 294 (222, 750)
Change from baseline in CRT [μm]
Visit Baseline 30 days 60 days 90 days
Mean (SD)
Not applicable
−120.5 (147) −160.0 (142) −124 (125)
Median (min, max) −81 (431, −41) −116 (456, 0) −103 (422, −18)
p value∗ 0.005 0.0004 0.001





























Figure 2: Boxplot of best-corrected visual acuity (BCVA) (logMAR) over 90 days. Mean BCVA increased significantly at all follow-up
(p ≤ 007), mainly at 60 days after surgery.
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The mean change from baseline in BCVA was statisti-
cally significant at all follow-up visits (p ≤ 007) as
reported by different authors [14–16]. A clinically signifi-
cant improvement in BCVA has been defined as ≥0.3 log-
MAR [26]. Agarwal et al. [14] reported a mean visual gain
of 18 letters at 12 weeks. Panozzo et al. [15] reported a
stable mean visual improvement of 18 letters at month 2
after treatment. In this study, according to this cut-off
value, the mean or median visual change (0.30± 0.28 log-
MAR; 0.30 logMAR) indicated a clinically significant
improvement at 60 days (2 months). An improve-
ment≥ 0.3 logMAR at at least 1 postsurgery time point
was reported in 8 patients (50%) who maintained that
improvement up to 90 days. Comparing the variations in
BCVA at different follow-up visits, no significant differ-
ence was observed. These results could be attributed to
the weak correlation between reduction in CRT and
improvement in BCVA, as reported by previous studies
[27, 28]. Also, clinical characteristics such as increasing
age, female sex, duration of diabetes, high HbA1c level at
the time of surgery, and moderate to severe retinopathy
have been associated with poor prognosis after cataract
surgery in diabetic patients [29–31]. So our functional out-
comes should be analyzed considering that nine patients
(56.3%) were female, the mean HbA1c level before surgery
was 7.76, and the mean duration of diabetes mellitus was
20.1 years.
In previous reports [14–16], the injection of Ozurdex in
combination with cataract surgery raised no safety concerns
with regard to IOP or other ocular or systemic complications.
So, in this study, there was only one case of elevated IOP
(28mmHg) occurring 10 days after cataract extraction,
which returned to normal after topic treatment. No case of
endophthalmitis was observed.
The power of this study is limited by the retrospective
design, small sample size, and lack of a control group. In
addition, the follow-up time is too short to decide on
retreatment with dexamethasone implant if macular edema
should recur even if these patients were sent to injection
service for the next follow-up. Another limitation was
the high interpatient variability regarding the study vari-
ables CRT and BCVA at baseline, which ranged between
270 μm and 789 μm and between 0.09 logMAR (normal
vision) and 1.00 logMAR (severe vision loss), respectively.
However, that interpatient variability could suggest the
efficacy of combined approach regardless of the severity
of cataract and macular edema.
In conclusion, the results of this study indicate that
intravitreal dexamethasone implant administration in
combination with phacoemulsification and IOL implanta-
tion may be safe and effective for morphologic and visual
outcomes in cataract and DME during the first 3 months
after surgery.
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Table 3: Best-corrected visual acuity (BCVA) over time.
Measured BCVA
Visit Baseline 30 days 60 days 90 days
Mean (logMAR± SD) 20/105 (0.72 ± 0.34) 20/60 (0.48 ± 0.28) 20/53 (0.42 ± 0.30) 20/57 (0.46 ± 0.39)
Median, logMAR (min, max) 0.55 (0.4, 1.39) 0.50 (0.00, 1) 0.45 (0.00, 1) 0.40 (0.00, 1.39)
Change from Baseline in BCVA
Visit Baseline 30 days 60 days 90 days
Mean, logMAR ± SD
not applicable
−0.24 ± 0.30 −0.30 ± 0.28 −0.26 ± 0.30
Median, logMAR (min, max) 0.15 (−0.20, 0.99) 0.30 (−0.10, 0.99) 0.25 (−0.30, 0.99)
p value∗ 0.007 0.0008 0.004
∗Weighted t-test for change versus baseline.
Table 4: Intraocular pressure (IOP) over time.
Measured IOP [mmHg]
Visit Baseline 10 days 20 days 30 days
Mean (SD) 15.7 (2.0) 16.0 (5.0) 14.2 (2.8) 14.5 (2.3)
Median (min, max) 15.5 (13, 20) 15.5 (9, 28) 14 (9, 18) 15 (10, 18)
Visit 40 days 50 days 60 days 90 days
Mean (SD) 15.1 (3.0) 14.9 (1.7) 14.9 (2.5) 16.4 (3.1)
Median (min, max) 15 (10, 20) 15 (11, 17) 16 (10, 18) 16.5 (11, 25)
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